查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1830616

前列腺癌治療市場（按治療機制、治療線、配方、分銷管道和最終用戶）—2025-2032 年全球預測

Prostate Cancer Therapeutics Market by Therapeutic Mechanism, Therapy Line, Formulation, Distribution Channel, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年前列腺癌治療市場規模將達到 175.9 億美元，複合年成長率為 6.50%。

主要市場統計數據
基準年2024年 106.2億美元
預計2025年 113.2億美元
預測年份：2032年 175.9億美元
複合年成長率（%） 6.50%

對不斷發展的臨床實踐、診斷整合和治療創新的前瞻性概述，這些正在重新定義全球前列腺癌的治療和管理方式

在分子診斷、新型治療方法和不斷發展的治療模式的推動下，前列腺癌的治療正在經歷重大變革時期。近年來，臨床醫生和研發人員已從廣泛的細胞毒性療法轉向精準治療策略，這些策略選擇性地靶向腫瘤生物學特性，並利用基因組學和成像技術發現的弱點。同時，放射性藥物和標靶治療的創新正在再形成臨床對疾病控制和耐受性的預期，促使臨床醫生重新考慮分期給藥順序和聯合用藥策略。

這種動態環境為藥物開發商、支付方、醫療保健提供者和患者權益組織帶來了新的機會和營運挑戰。相關人員越來越重視在治療路徑早期整合診斷檢測，以指導個人化治療方案。同時，臨床試驗設計也在不斷發展，涵蓋生物標記富集、自適應框架和分散式要素，以加快入組速度並提高患者代表性。這些轉變凸顯了腫瘤學家、核醫學專家、遺傳諮詢師和衛生系統之間的跨學科合作日益重要，有助於將創新轉化為永續的治療標準。

診斷突破、放射性藥物的應用、標靶藥物以及新的商業模式如何重塑前列腺癌的治療通訊協定和護理可及性

前列腺癌治療領域正在經歷一場變革性的轉變，其驅動力在於診斷精準度、新型治療方法和策略性商業化方法的融合。 PSMA標靶成像和不斷擴展的基因組組合等診斷進展，如今為臨床醫生提供了可操作的數據，用於指導標靶治療的選擇，從而能夠更早、更準確地識別PARP抑制劑和放射性配體療法的候選藥物。同時，放射性藥物正從利基臨床實驗藥物轉變為針對特定患者群體的成熟治療方案，從而改變臨床路徑和供應鏈需求。

隨著雄性激素受體路徑抑制劑和新一代小分子藥物在抗藥性機制方面的不斷改進，標靶藥物的創新正在加速。免疫療法正在最佳化患者選擇，以提高迄今為止觀察到的適度緩解率，而細胞療法和治療性疫苗仍然是活躍的研究方向。製造商和醫療保健提供者正在合作進行專業分銷、低溫運輸物流和患者援助項目，以確保患者能夠及時獲得需要特殊處理的治療藥物。這些累積的變化正在推動醫療保健系統重新思考治療流程和報銷策略，以適應高成本、更高價值的干涉措施。

2025年進口藥品投入品和專用放射性藥物材料的關稅政策變化對營運、供應鏈和取得的影響

影響關稅和跨境貿易的政策變化可能會對依賴專業化投入和物流的療法產生集中的下游影響。進口活性藥物原料藥、前驅化學品和放射性化學品的關稅上調，可能會增加製造商以及受託製造廠商的生產成本，進而影響定價策略、庫存緩衝和供應協議。鑑於放射性藥物生產和分銷的技術複雜性和監管限制，即使關稅制度的微小變化也可能使採購決策複雜化，並迫使企業進行短期營運調整。

為了應對關稅帶來的成本壓力，相關人員已開始評估降低風險的策略。這些措施包括實現供應商組合多樣化、重新談判長期採購合約、加速近岸外包和區域製造夥伴關係，以及增加對國內放射性配體合成能力的投資。此外，衛生系統和付款人可能會加強對比較有效性和現實世界結果的審查，以證明高成本治療方法的報銷是合理的。在臨床方面，製造商必須與物流供應商更緊密地合作，以確保可預測的時間敏感療法的供應，臨床試驗贊助者可能需要建立更大的用於多中心臨床試驗的在臨床實驗藥物安全庫存。總而言之，這些營運和策略轉變將決定關稅變化如何影響新療法的可及性、可負擔性以及患者獲得新療法的速度。

特定細分領域的影響塑造了治療機制、治療線、配方、分銷管道和最終用戶動態的臨床價值提案和產業計畫

詳細的細分視圖闡明了臨床機會和商業性複雜性的交會點。根據治療機制，市場分為化療、荷爾蒙療法、免疫治療、放射性藥物和標靶治療。化療包括鉑化合物和紫杉烷類。荷爾蒙療法細分為抗雄性激素、CYP17 抑制劑、GnRH促效劑和 GnRH 拮抗劑。免疫療法分為癌症疫苗、細胞療法和查核點抑制劑。放射性藥物分為 α 放射體和 BETA 放射體。標靶治療分為單株抗體、PAR 抑制劑和蛋白酪氨酸激酶抑制劑。根據治療線，治療途徑分為一線、二線和三線或以上。根據劑型，市場分為注射劑和口服藥物。根據銷售管道，管道包括醫院藥房、網路藥房和零售藥房。根據最終用戶，分析涵蓋癌症中心、居家照護提供者、醫院和專科診所。

從策略角度來看，治療機制細分揭示了研發投資將帶來最大差異化的領域。目前，放射性藥物和標靶藥物為個人化治療提供了最有力的途徑，而細胞毒性化學療法在某些臨床場景中仍發揮作用。治療線細分錶明需要價值提案和證據生成，因為學名藥的核准通常依賴生物標記定義的人群。劑型細分推動商業規劃，因為口服藥物優先考慮依從性計劃和患者支持基礎設施，而注射劑和放射性標記產品則需要專門的給藥地點和低溫運輸物流。分銷管道和最終用戶細分凸顯了根據供應商能力、報銷環境和患者偏好客製化分銷策略的必要性，以最大限度地提高及時性並最佳化護理途徑。

透過對美洲、歐洲、中東和非洲以及亞太地區的採用、基礎設施準備和報銷細節進行比較分析，確定治療方法所獲得的軌跡

區域動態顯著影響前列腺癌治療的採用、報銷和發展重點。在美洲，臨床創新和商業性發布能力仍然高度集中，這得益於既定的監管途徑和先進診斷技術的廣泛採用。這種環境促進了放射性配體療法和生物標記主導的標靶藥物的快速商業化，同時也產生了需要強力的真實世界證據來支持持續可及性的付款人審查。相較之下，歐洲、中東和非洲在定價政策、報銷計畫和醫療保健基礎設施方面表現出差異性。一些歐洲市場正在其國家醫療保健系統中迅速採用新的診斷方法和高成本治療方法，而其他市場則在逐步取得進展。一些中東和北非國家正在選擇性地投資核子醫學和專門的腫瘤中心，作為更廣泛的醫療保健系統加強工作的一部分。

亞太地區臨床試驗活動快速發展，生產能力不斷提升，報銷成熟度也參差不齊。該地區多個國家正在成為重要的臨床開發中心，為生物標記主導的研究提供大量患者群體，並不斷提升核醫學能力以支持放射性藥物計畫。然而，獲取途徑仍然不均衡，價格壓力和區域指南調整正在影響藥物的吸收。跨地區臨床試驗的跨境合作、診斷標準的協調以及對時間敏感型治療的物流投資是通用的戰略重點，這些將決定藥物的採用速度以及在不久的將來受益最大的患者群體。

深入了解公司在前列腺癌治療領域塑造競爭地位和商業準備的策略重點、夥伴關係框架和能力投資

前列腺癌治療領域的企業策略體現了其對標靶治療、策略夥伴關係和真實世界證據產生的深度投資。現有製藥公司正將資源集中於PARP抑制劑、下一代雄激素受體拮抗劑，並推進已通過核准藥物的生命週期管理，同時與核子醫學專家和契約製造合作，將放射性配體療法商業化。規模較小的生物技術和專科公司則專注於生物標記驅動的適應症，並尋求細胞療法和治療性疫苗等利基療法，以加速臨床開發並最大限度地實現差異化。

縱觀競爭格局，那些展現出綜合實力（例如診斷夥伴關係、注射劑和放射性藥物分銷網路以及強大的患者支持計劃）的公司，在商業化準備方面正獲得顯著優勢。策略性併購和授權交易正在重塑投資組合，使大型公司能夠將專業技術引入內部，而中型市場公司則能夠利用合作夥伴的商業化管道。此外，投資於數位互動工具、分散臨床臨床實驗營運和長期真實世界結果研究的公司，正在定位自己，以便更快地響應付款方的需求和臨床醫生的偏好。這些企業行動正在加速將新科學轉化為可及的治療方法，同時重塑合作夥伴生態系統。

為商業、臨床和供應鏈領導者提供實用且以證據為中心的策略，以加速採用、保護獲取途徑並減輕治療開發中的政策主導風險

產業領導者應優先考慮將科學差異化與營運準備結合的合作策略。首先，將診斷技術許可引入途徑整合到臨床開發項目中，以確保在產品上市前建立伴隨檢測和患者識別能力。與診斷技術提供者和付款方的早期合作可以簡化許可引入和報銷談判。其次，透過多元化供應商、就關鍵投入品進行多年期合約談判以及擴大區域製造夥伴關係來增強供應鏈的彈性，以降低關稅和物流風險。第三，投資於證據生成，不僅包括關鍵臨床試驗，還包括註冊登記和實用研究，以捕捉現實世界的療效、安全性和健康經濟成果，從而支持報銷並增強處方醫生的信心。

除了這些核心行動之外，企業還應重新評估分銷策略，以應對居家醫療和專科診所在注射劑和放射性藥物方面日益成長的作用，並設計患者援助項目，以提高口服藥物的依從性，並促進患者及時獲得複雜療法。企業也應深化與關鍵高階主管的跨部門合作，並與付款方進行對話，共同製定反映長期臨床效益的價值框架。最後，企業應採用靈活的商業模式，包括在適當情況下採用風險分擔安排和基於結果的契約，並保持情景規劃能力，以快速應對政策變化、資費調整和不斷發展的臨床指南。

透過整合二手證據、臨床試驗和監管審查、專家訪談和情境檢驗的嚴格、多方法研究途徑獲得可行的見解

調查方法結合了系統性的二手資料研究、專家的初步調查和多源數據三角測量，從而全面觀點治療、監管和商業動態。二手資料研究涵蓋了同行評審文獻、臨床試驗註冊庫、監管公告和公司出版物中的治療機制、近期核准和研發管線活動。初步資料研究包括與腫瘤學、核子醫學領域的關鍵意見領袖、供應鏈專業人士、付款方和臨床營運專家進行結構化訪談，以檢驗趨勢、支持臨床決策模式並強調與專科產品分銷和管理相關的營運挑戰。

透過對多個資料輸入進行交叉驗證，並結合情境分析，檢驗政策和供應中斷的影響，增強了分析的嚴謹性。調查方法強調對臨床試驗證據和監管軌跡進行定性檢驗和情境解讀，而非定量預測，並結合相關人員研討會，確保最終建議符合現實的營運約束和策略要求。這種多層次的方法為商業、臨床開發和供應鏈職能部門的決策者提供了可靠且可操作的洞察。

臨床創新、營運要務和合作重點的策略整合，以建立永續取得和改善患者治療效果的途徑

前列腺癌治療格局的演變既帶來了巨大的機遇，也帶來了營運的複雜性。標靶藥物、放射性藥物和診斷精準度的進步，正在推動臨床模式轉向更個人化的策略轉變，而分銷、生產和報銷體系必須適應需要專業處理和證據來證明長期價值的療法。那些將科學創新與切合實際的產業計畫相結合的組織——那些能夠增強供應彈性、發展診斷和分銷夥伴關係並投資於現實世界結果研究的組織——將最有能力將突破性進展轉化為永續的患者可及性。

展望未來，產業、臨床和政策相關人員之間的合作對於平衡快速治療創新與公平可及性和成本效益至關重要。透過預測付款人預期、監管要求和當地基礎設施限制的變化，相關人員可以主動設計既能帶來臨床效益又能確保營運可行性的開發和商業化方案。今天的策略選擇將決定哪些治療方法能夠有效地惠及患者，以及哪些方法將成為下一代前列腺癌治療的標準。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • BRCA 突變轉移性去勢抗性攝護腺癌患者擴大採用 PARP 抑制劑
  • 加速將PSMA標靶放射配體療法整合到晚期攝護腺癌的二線治療通訊協定中
  • 下一代雄性激素受體分解藥物在激素敏感性前列腺癌的早期臨床試驗中顯示出良好的結果
  • 整合以液態生物檢體為基礎的基因組分析，以個人化前列腺癌治療途徑中的治療決策
  • 開發針對 PSMA 和 CD3 的雙特異性抗體療法，以促進 T 細胞介導的前列腺腫瘤根除
  • 新興的聯合治療策略將新型免疫療法藥物與現有的前列腺癌荷爾蒙療法結合
  • PSMA PET放射性藥物的進展使得前列腺癌的早期檢測和即時監測成為可能
  • 擴大人工智慧預測分析的應用，以最佳化前列腺癌的患者分層和治療方法方案

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

第8章前列腺癌治療市場（依治療機制）

  • 化療
    • 含鉑類藥物
    • 紫杉烷類
  • 荷爾蒙療法
    • 抗雄激素
    • CYP17抑制劑
    • GnRH促效劑
    • GnRH拮抗劑
  • 免疫療法
    • 癌症疫苗
    • 細胞療法
    • 查核點抑制劑
  • 放射性藥物
    • α發射體
    • BETA射線發射器
  • 標靶治療
    • 單株抗體
    • PARP抑制劑
    • 蛋白酪氨酸激酶抑制劑

第9章前列腺癌治療市場（依治療線）

  • 初級治療
  • 二級處理
  • 三線治療及後續治療

第 10 章前列腺癌治療市場（按劑型）

  • 注射
  • 口服

第 11 章前列腺癌治療市場（依通路）

  • 醫院藥房
  • 網路藥局
  • 零售藥局

第 12 章前列腺癌治療市場（按最終用戶）

  • 癌症中心
  • 居家照護提供者
  • 醫院
  • 專科診所

第13章前列腺癌治療市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章前列腺癌治療市場（依類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第 15 章前列腺癌治療市場（按國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Astellas Pharma Inc.
    • Pfizer Inc.
    • Johnson & Johnson
    • F. Hoffmann-La Roche AG
    • Novartis AG
    • Bayer AG
    • AstraZeneca PLC
    • Sanofi SA
    • Bristol-Myers Squibb Company
    • Merck & Co., Inc.
Product Code: MRR-4342CA3266BF

The Prostate Cancer Therapeutics Market is projected to grow by USD 17.59 billion at a CAGR of 6.50% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 10.62 billion
Estimated Year [2025] USD 11.32 billion
Forecast Year [2032] USD 17.59 billion
CAGR (%) 6.50%

A forward-looking overview of evolving clinical practice, diagnostic integration, and therapeutic innovation that are redefining how prostate cancer is treated and managed globally

Prostate cancer therapeutics are undergoing a period of meaningful transformation driven by advances in molecular diagnostics, novel therapeutic modalities, and evolving care delivery models. Over the last several years, clinicians and developers have shifted from broad cytotoxic approaches toward precision strategies that selectively target tumor biology and exploit vulnerabilities identified through genomic and imaging technologies. In parallel, innovations in radiopharmaceuticals and targeted therapies are reshaping clinical expectations for disease control and tolerability, prompting clinicians to rethink sequencing and combination strategies for different stages of disease.

This dynamic environment has created new opportunities and operational challenges for pharmaceutical developers, payers, providers, and patient support organizations. Stakeholders increasingly prioritize integration of diagnostic testing early in the care pathway to guide personalized regimens. Meanwhile, clinical trial design is adapting to include biomarker-enrichment, adaptive frameworks, and decentralized elements to accelerate enrollment and broaden patient representation. These shifts underscore the growing importance of multi-disciplinary collaboration among oncologists, nuclear medicine specialists, genetic counselors, and health systems to translate innovation into sustainable standards of care.

How diagnostic breakthroughs, radiopharmaceutical adoption, targeted agents, and new commercial models are collectively reshaping prostate cancer treatment protocols and access

The prostate cancer therapeutic landscape is experiencing transformative shifts driven by convergence of diagnostic precision, novel modalities, and strategic commercialization approaches. Diagnostic advances such as PSMA-targeted imaging and expanded genomic panels now provide clinicians with actionable data that inform targeted therapy selection, enabling earlier and more accurate identification of candidates for PARP inhibitors and radioligand therapies. Concurrently, radiopharmaceuticals have moved from niche investigational status to established therapeutic options for selected patient populations, altering both clinical pathways and supply chain requirements.

Innovation in targeted agents continues apace with incremental improvements in androgen receptor pathway inhibitors and next-generation small molecules that address resistance mechanisms. Immunotherapy efforts are refining patient selection to improve the modest response rates observed to date, while cell-based approaches and therapeutic vaccines persist as active research avenues. Commercial models are adapting to these scientific changes: manufacturers and providers are collaborating on specialized distribution, cold-chain logistics, and patient support programs to ensure timely access for therapies that require unique handling. These cumulative changes are propelling health systems to revise treatment algorithms and reimbursement strategies to accommodate higher-cost, higher-value interventions.

Operational, supply chain, and access implications of tariff policy changes on imported pharmaceutical inputs and specialized radiopharmaceutical materials through 2025

Policy shifts affecting tariffs and cross-border trade can have concentrated downstream effects on therapeutics that rely on specialized inputs and logistics. Increased tariffs on imported active pharmaceutical ingredients, precursor chemicals, or radiochemistry materials can raise production costs for manufacturers and contract development and manufacturing organizations, which in turn may influence pricing strategy, inventory buffers, and supply agreements. Given the technical complexity and regulatory constraints surrounding radiopharmaceutical production and distribution, even modest changes in tariff regimes can complicate sourcing decisions and necessitate near-term operational adjustments.

In response to tariff-driven cost pressures, stakeholders are already evaluating strategies to mitigate exposure. These measures include diversifying supplier portfolios, renegotiating long-term procurement contracts, accelerating nearshoring or regional manufacturing partnerships, and increasing investment in domestic capacity for radioligand synthesis. Additionally, health systems and payers may intensify scrutiny of comparative effectiveness and real-world outcomes to justify reimbursement for higher-cost therapies. Clinically, manufacturers must collaborate more closely with logistics providers to ensure predictable supply for time-sensitive therapies, and sponsors may need to build larger safety stocks for investigational agents used in multicenter trials. Collectively, these operational and strategic shifts will determine how tariff changes influence access, affordability, and the pace at which new therapies reach patients.

Segment-specific implications across therapeutic mechanism, therapy line, formulation, distribution channel, and end-user dynamics that shape clinical value propositions and operational planning

A granular view of segmentation clarifies where clinical opportunity and commercial complexity intersect. Based on therapeutic mechanism, the landscape spans Chemotherapy, Hormone Therapy, Immunotherapy, Radiopharmaceuticals, and Targeted Therapy; the Chemotherapy category further includes Platinum Compounds and Taxanes; the Hormone Therapy category is subdivided into Antiandrogens, CYP17 Inhibitors, GnRH Agonists, and GnRH Antagonists; Immunotherapy is examined through Cancer Vaccines, Cell Therapy, and Checkpoint Inhibitors; Radiopharmaceuticals are analyzed as Alpha Emitters and Beta Emitters; and Targeted Therapy encompasses Monoclonal Antibodies, Parp Inhibitors, and Tyrosine Kinase Inhibitors. Based on therapy line, therapeutic pathways are differentiated into First Line, Second Line, and Third Line and Beyond. Based on formulation, modalities are classified as Injectable and Oral. Based on distribution channel, channels include Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies. Based on end user, the analysis considers Cancer Centers, Homecare Providers, Hospitals, and Specialty Clinics.

From a strategic standpoint, therapeutic mechanism segmentation highlights where R&D investment yields the greatest differentiation; radiopharmaceuticals and targeted agents currently offer the strongest pathway to personalized outcomes, while cytotoxic chemotherapy continues to play a role in specific clinical scenarios. Therapy line segmentation informs value proposition and evidence generation needs, with later-line approvals frequently relying on biomarker-defined populations. Formulation segmentation drives commercial planning, since oral agents prioritize adherence initiatives and patient support infrastructure, whereas injectable or radiolabeled products necessitate specialized administration sites and cold-chain logistics. Distribution channel and end-user segmentation underscore the operational necessity of aligning distribution strategies with site capabilities, reimbursement environments, and patient preferences to maximize timely access and optimize care pathways.

Comparative analysis of regional adoption, infrastructure readiness, and reimbursement nuances across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine therapeutic access trajectories

Regional dynamics materially influence adoption, reimbursement, and development priorities for prostate cancer therapeutics. In the Americas, clinical innovation and commercial launch capacity remain highly concentrated, supported by well-established regulatory pathways and broad adoption of advanced diagnostics; this environment incentivizes rapid commercialization of radioligand therapies and biomarker-driven targeted agents, while also generating payer scrutiny that requires robust real-world evidence to support durable access. In contrast, Europe, Middle East & Africa exhibits heterogeneity in pricing policies, reimbursement timelines, and healthcare infrastructure; some European markets adopt new diagnostics and high-cost therapies rapidly under national health systems while others progress incrementally, and countries across the Middle East and Africa are selectively investing in nuclear medicine and specialty oncology centers as part of broader health system strengthening efforts.

Asia-Pacific represents a mix of rapid clinical trial activity, expanding manufacturing capacity, and variable reimbursement maturity. Several countries in the region are emerging as important clinical development hubs, offering large patient populations for biomarker-driven studies and growing nuclear medicine capabilities to support radiopharmaceutical programmes. However, access remains uneven, with pricing pressure and local guideline adaptation influencing uptake. Across all regions, cross-border collaboration on clinical trials, harmonization of diagnostic standards, and investment in logistics for time-sensitive therapies are common strategic priorities that will determine the pace of adoption and the patient populations that will benefit most in the near term.

Insights into corporate strategic priorities, partnership frameworks, and capability investments that determine competitive positioning and commercialization readiness in prostate cancer therapeutics

Corporate strategies in prostate cancer therapeutics reflect deep investments in targeted modalities, strategic partnerships, and real-world evidence generation. Established pharmaceutical firms have concentrated resources on advancing PARP inhibitors, next-generation androgen receptor antagonists, and lifecycle management of approved assets, while also entering collaborations with nuclear medicine specialists and contract manufacturers to commercialize radioligand therapies. Smaller biotech and specialty companies are advancing niche approaches such as cell therapies and therapeutic vaccines, focusing on biomarker-enriched indications to expedite clinical development and maximize differentiation.

Across the competitive landscape, companies that demonstrate integrated capabilities-combining diagnostic partnerships, distribution networks for injectable and radiopharmaceutical products, and robust patient support programs-achieve a clear advantage in commercialization readiness. Strategic M&A and licensing deals continue to realign portfolios, enabling larger players to internalize specialized technologies and enabling mid-sized companies to leverage partners' commercialization channels. Additionally, firms investing in digital engagement tools, decentralized trial operations, and long-term real-world outcomes research position themselves to respond to payer demands and clinician preferences more rapidly. Collectively, these corporate actions are accelerating the translation of novel science into accessible treatment options while reshaping partner ecosystems.

Practical, evidence-focused strategies for commercial, clinical, and supply chain leaders to accelerate adoption, protect access, and mitigate policy-driven risks in therapeutic development

Industry leaders should prioritize coordinated strategies that align scientific differentiation with operational readiness. First, integrate diagnostic adoption pathways into clinical development programs to ensure companion tests and patient identification capabilities are established ahead of launch; early collaboration with diagnostic providers and payers will streamline uptake and reimbursement discussions. Second, strengthen supply chain resiliency by diversifying suppliers, negotiating multi-year agreements for critical inputs, and expanding regional manufacturing partnerships to mitigate tariff and logistics risks. Third, invest in evidence generation that extends beyond pivotal trials to include registries and pragmatic studies capturing real-world effectiveness, safety, and health economic outcomes to support reimbursement and prescriber confidence.

Beyond these core actions, organizations should re-evaluate distribution strategies to accommodate the growing role of homecare and specialty clinics for injectable and radiopharmaceutical products, while designing patient support programs that improve adherence for oral agents and facilitate timely access for complex therapies. Firms must also cultivate cross-disciplinary KOL engagement and payer dialogues to co-develop value frameworks that reflect long-term clinical benefit. Lastly, embrace flexible commercial models including risk-sharing arrangements and outcomes-based contracting where appropriate, and maintain scenario planning capabilities to respond rapidly to policy shifts, tariff adjustments, and evolving clinical guidelines.

A rigorous multi-method research approach integrating secondary evidence, clinical trial and regulatory review, expert interviews, and scenario validation to produce actionable insights

The research approach combined systematic secondary research, primary expert engagement, and multi-source data triangulation to assemble a comprehensive perspective on therapeutic, regulatory, and commercial dynamics. Secondary research drew on peer-reviewed literature, clinical trial registries, regulatory announcements, and company publications to map therapeutic mechanisms, recent approvals, and pipeline activity. Primary research consisted of structured interviews with key opinion leaders in oncology, nuclear medicine, supply chain professionals, payers, and clinical operations experts to validate trends, corroborate clinical decision-making patterns, and surface operational challenges tied to distribution and administration of specialized products.

Analytical rigor was reinforced through cross-validation of findings across multiple data inputs and scenario analysis to test susceptibility to policy and supply disruptions. The methodology emphasized qualitative synthesis and contextual interpretation of clinical trial evidence and regulatory trajectories rather than quantitative projections, and it incorporated stakeholder workshops to ensure the final recommendations align with practical operational constraints and strategic imperatives. This layered approach supports robust, actionable insight for decision-makers across commercial, clinical development, and supply chain functions.

A strategic synthesis of clinical innovation, operational imperatives, and collaborative priorities that frames the pathway to sustainable access and improved patient outcomes

The evolving prostate cancer therapeutics landscape presents both profound opportunity and operational complexity. Advances in targeted agents, radiopharmaceuticals, and diagnostic precision are shifting clinical paradigms toward more personalized strategies, while distribution, manufacturing, and reimbursement systems must adapt to accommodate therapies that require specialized handling and evidence to demonstrate long-term value. Organizations that align scientific innovation with pragmatic operational planning-strengthening supply resilience, forging diagnostic and distribution partnerships, and investing in real-world outcomes research-will be best positioned to translate breakthroughs into sustainable patient access.

Looking ahead, collaboration across industry, clinical, and policy stakeholders will be essential to reconcile rapid therapeutic innovation with equitable access and cost-effectiveness. By anticipating shifts in payer expectations, regulatory requirements, and regional infrastructure constraints, stakeholders can proactively design development and commercialization programs that deliver clinical benefit while safeguarding operational viability. The strategic choices made today will determine which therapies reach patients efficiently and which approaches set the standard for next-generation prostate cancer care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rising adoption of PARP inhibitors for metastatic castration-resistant prostate cancer in patients with BRCA mutations
  • 5.2. Accelerating integration of PSMA-targeted radioligand therapy into second-line treatment protocols for advanced prostate cancer
  • 5.3. Expansion of next-generation androgen receptor degraders showing promising outcomes in early hormone-sensitive prostate cancer trials
  • 5.4. Integration of liquid biopsy-based genomic profiling to personalize treatment decisions in prostate cancer care pathways
  • 5.5. Development of bispecific antibody therapies targeting PSMA and CD3 to enhance T-cell mediated prostate tumor eradication
  • 5.6. Emergence of combination strategies pairing novel immunotherapy agents with existing hormonal therapies in prostate cancer
  • 5.7. Advances in PSMA PET radiopharmaceuticals enabling earlier detection and real-time monitoring of prostate cancer progression
  • 5.8. Growing utilization of artificial intelligence predictive analytics to optimize patient stratification and therapeutic selection in prostate cancer

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Prostate Cancer Therapeutics Market, by Therapeutic Mechanism

  • 8.1. Chemotherapy
    • 8.1.1. Platinum Compounds
    • 8.1.2. Taxanes
  • 8.2. Hormone Therapy
    • 8.2.1. Antiandrogens
    • 8.2.2. CYP17 Inhibitors
    • 8.2.3. GnRH Agonists
    • 8.2.4. GnRH Antagonists
  • 8.3. Immunotherapy
    • 8.3.1. Cancer Vaccines
    • 8.3.2. Cell Therapy
    • 8.3.3. Checkpoint Inhibitors
  • 8.4. Radiopharmaceuticals
    • 8.4.1. Alpha Emitters
    • 8.4.2. Beta Emitters
  • 8.5. Targeted Therapy
    • 8.5.1. Monoclonal Antibodies
    • 8.5.2. Parp Inhibitors
    • 8.5.3. Tyrosine Kinase Inhibitors

9. Prostate Cancer Therapeutics Market, by Therapy Line

  • 9.1. First Line
  • 9.2. Second Line
  • 9.3. Third Line And Beyond

10. Prostate Cancer Therapeutics Market, by Formulation

  • 10.1. Injectable
  • 10.2. Oral

11. Prostate Cancer Therapeutics Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
  • 11.2. Online Pharmacies
  • 11.3. Retail Pharmacies

12. Prostate Cancer Therapeutics Market, by End User

  • 12.1. Cancer Centers
  • 12.2. Homecare Providers
  • 12.3. Hospitals
  • 12.4. Specialty Clinics

13. Prostate Cancer Therapeutics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Prostate Cancer Therapeutics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Prostate Cancer Therapeutics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Astellas Pharma Inc.
    • 16.3.2. Pfizer Inc.
    • 16.3.3. Johnson & Johnson
    • 16.3.4. F. Hoffmann-La Roche AG
    • 16.3.5. Novartis AG
    • 16.3.6. Bayer AG
    • 16.3.7. AstraZeneca PLC
    • 16.3.8. Sanofi S.A.
    • 16.3.9. Bristol-Myers Squibb Company
    • 16.3.10. Merck & Co., Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. PROSTATE CANCER THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. PROSTATE CANCER THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. PROSTATE CANCER THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY PLATINUM COMPOUNDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY PLATINUM COMPOUNDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY PLATINUM COMPOUNDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY PLATINUM COMPOUNDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY PLATINUM COMPOUNDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY PLATINUM COMPOUNDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TAXANES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TAXANES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TAXANES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TAXANES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TAXANES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TAXANES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY ANTIANDROGENS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY ANTIANDROGENS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY ANTIANDROGENS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY ANTIANDROGENS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY ANTIANDROGENS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY ANTIANDROGENS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CYP17 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CYP17 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CYP17 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CYP17 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CYP17 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CYP17 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY GNRH AGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY GNRH AGONISTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY GNRH AGONISTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY GNRH AGONISTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY GNRH AGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY GNRH AGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY GNRH ANTAGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY GNRH ANTAGONISTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY GNRH ANTAGONISTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY GNRH ANTAGONISTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY GNRH ANTAGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY GNRH ANTAGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CANCER VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CANCER VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CANCER VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CANCER VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CANCER VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY ALPHA EMITTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY ALPHA EMITTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY ALPHA EMITTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY ALPHA EMITTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY ALPHA EMITTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY ALPHA EMITTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY BETA EMITTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY BETA EMITTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY BETA EMITTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY BETA EMITTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY BETA EMITTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY BETA EMITTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY PARP INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY PARP INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY PARP INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY PARP INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY PARP INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY PARP INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THIRD LINE AND BEYOND, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THIRD LINE AND BEYOND, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THIRD LINE AND BEYOND, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THIRD LINE AND BEYOND, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THIRD LINE AND BEYOND, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THIRD LINE AND BEYOND, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CANCER CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CANCER CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CANCER CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CANCER CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CANCER CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CANCER CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HOMECARE PROVIDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HOMECARE PROVIDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HOMECARE PROVIDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HOMECARE PROVIDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HOMECARE PROVIDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HOMECARE PROVIDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 214. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 215. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2024 (USD MILLION)
  • TABLE 216. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2025-2032 (USD MILLION)
  • TABLE 217. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 218. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 219. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 220. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 221. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 222. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 223. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 224. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 225. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 226. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 227. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
  • TABLE 228. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2025-2032 (USD MILLION)
  • TABLE 229. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 230. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 231. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 232. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 233. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 234. AMERICAS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. NORTH AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2024 (USD MILLION)
  • TABLE 238. NORTH AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2025-2032 (USD MILLION)
  • TABLE 239. NORTH AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 240. NORTH AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 242. NORTH AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 244. NORTH AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 245. NORTH AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 246. NORTH AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 247. NORTH AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 248. NORTH AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
  • TABLE 250. NORTH AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2025-2032 (USD MILLION)
  • TABLE 251. NORTH AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 252. NORTH AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 253. NORTH AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 254. NORTH AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 255. NORTH AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 256. NORTH AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. LATIN AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. LATIN AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2024 (USD MILLION)
  • TABLE 260. LATIN AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2025-2032 (USD MILLION)
  • TABLE 261. LATIN AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 262. LATIN AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 263. LATIN AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 264. LATIN AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 265. LATIN AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 266. LATIN AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 267. LATIN AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 268. LATIN AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 269. LATIN AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 270. LATIN AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 271. LATIN AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
  • TABLE 272. LATIN AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2025-2032 (USD MILLION)
  • TABLE 273. LATIN AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 274. LATIN AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 275. LATIN AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 276. LATIN AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 277. LATIN AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 278. LATIN AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)

TABLE 2